SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Armand Alex)
 

Sökning: WFRF:(Armand Alex) > Five-year follow-up...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005757naa a2200505 4500
001oai:DiVA.org:uu-515675
003SwePub
008231116s2023 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5156752 URI
0247 a https://doi.org/10.1182/blood.20220193862 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Armand, Philippeu Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.;Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.4 aut
2451 0a Five-year follow-up of KEYNOTE-087 :b pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma
264 1b American Society of Hematology,c 2023
338 a print2 rdacarrier
520 a Previous analyses of the phase 2 KEYNOTE-087 (NCT02453594) trial of pembrolizumab monotherapy demonstrated effective antitumor activity with acceptable safety in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL). However, long-term response durability and outcome of patients who receive a second course after treatment discontinuation after complete response (CR) remain of clinical interest. We present KEYNOTE-087 data after >5 years of median follow-up. Patients with R/R cHL and progressive disease (PD) after autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV; cohort 1), salvage chemotherapy and BV without ASCT (cohort 2), or ASCT without subsequent BV (cohort 3), received pembrolizumab for <= 2 years. Patients in CR who discontinued treatment and subsequently experienced PD were eligible for second-course pembrolizumab. Primary end points were the objective response rate (ORR) using blinded central review and safety. The median follow-up was 63.7 months. ORR was 71.4% (95% confidence interval [CI], 64.8-77.4; CR, 27.6%; partial response, 43.8%). Median duration of response (DOR) was 16.6 months; median progression-free survival was 13.7 months. A quarter of responders, including half of complete responders, maintained a response for >= 4 years. Median overall survival was not achieved. Among 20 patients receiving second-course pembrolizumab, ORR for 19 evaluable patients was 73.7% (95% CI, 48.8-90.8); median DOR was 15.2 months. Any-grade treatment-related adverse events occurred in 72.9% of patients and grade 3 or 4 adverse events occurred in 12.9% of patients; no treatment-related deaths occurred. Single-agent pembrolizumab can induce durable responses, particularly in patients achieving CR. Second-course pembrolizumab frequently reinduced sustained responses after relapse from initial CR.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Zinzani, Pier Luigiu Azienda Osped Univ Bologna, Ist Ricovero & Cura Carattere Sci, Ist Ematol Seragnoli, Bologna, Italy.;Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy.4 aut
7001 a Lee, Hun Juu Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA.4 aut
7001 a Johnson, Nathalie A.u Jewish Gen Hosp, Dept Med, Montreal, PQ, Canada.4 aut
7001 a Brice, Paulineu Hop St Louis, Hematooncol, Paris, France.4 aut
7001 a Radford, Johnu Christie NHS Fdn Trust, Dept Med Oncol, NIHR Clin Res Facil, Manchester, England.;Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, England.4 aut
7001 a Ribrag, Vincentu Gustave Roussy, Early Drug Dev Dept DITEP, Villejuif, France.4 aut
7001 a Molin, Daniel,d 1969-u Uppsala universitet,Cancerimmunterapi4 aut0 (Swepub:uu)danimoli
7001 a Vassilakopoulos, Theodoros P.u Natl & Kapodistrian Univ Athens, Laikon Gen Hosp, Dept Hematol & Bone Marrow Transplantat, Athens, Greece.4 aut
7001 a Tomita, Akihirou Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Japan.4 aut
7001 a von Tresckow, Bastianu Univ Cologne, Med Fac, Dept Internal Med 1, Cologne, Germany.;Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Hematol & Stem Cell Transplantat, Essen, Germany.;Univ Cologne, Univ Hosp Cologne, Cologne, Germany.4 aut
7001 a Shipp, Margaret A.u Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.4 aut
7001 a Herrera, Alex F.u City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA USA.4 aut
7001 a Lin, Jianxinu Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.4 aut
7001 a Kim, Eunheeu Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.4 aut
7001 a Chakraborty, Samhitau Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.4 aut
7001 a Marinello, Patriciau Merck & Co Inc, Dept Med Oncol, Rahway, NJ USA.4 aut
7001 a Moskowitz, Craig H.u Univ Miami, Sylvester Comprehens Canc Ctr, Dept Med, Miami, FL USA.4 aut
7102 a Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.;Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.b Azienda Osped Univ Bologna, Ist Ricovero & Cura Carattere Sci, Ist Ematol Seragnoli, Bologna, Italy.;Univ Bologna, Dipartimento Sci Med & Chirurg, Bologna, Italy.4 org
7730 t Bloodd : American Society of Hematologyg 142:10, s. 878-886q 142:10<878-886x 0006-4971x 1528-0020
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-515675
8564 8u https://doi.org/10.1182/blood.2022019386

Hitta via bibliotek

  • Blood (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy